Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
3(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
4
33%
Ph phase_2
4
33%
Ph phase_1
4
33%

Phase Distribution

4

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
4(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(5)
Completed(6)
Other(1)

Detailed Status

Completed6
Active, not recruiting3
Not yet recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (33.3%)
Phase 24 (33.3%)
Phase 34 (33.3%)

Trials by Status

not_yet_recruiting217%
completed650%
unknown18%
active_not_recruiting325%

Recent Activity

3 active trials
Showing 5 of 12
completedphase_1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

NCT06762600
not_yet_recruitingphase_1

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

NCT07540754
active_not_recruitingphase_3

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

NCT07285902
completedphase_3

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

NCT06396429
active_not_recruitingphase_3

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

NCT06650007
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06762600Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

Completed
NCT07540754Phase 1

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

Not Yet Recruiting
NCT07285902Phase 3

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Active Not Recruiting
NCT06396429Phase 3

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Completed
NCT06650007Phase 3

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

Active Not Recruiting
NCT06792955Phase 1

The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution

Completed
NCT06649344Phase 3

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Active Not Recruiting
NCT05966272Phase 2

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Completed
NCT05881837Phase 2

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Completed
NCT06654960Phase 1

Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects

Completed
NCT06565871Phase 2

A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea

Not Yet Recruiting
NCT06054698Phase 2

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12